Nav: Home

Gene therapy can protect against ALS and SMA-related cell death

February 17, 2020

Researchers at Karolinska Institutet in Sweden and the University of Milan in Italy have identified a gene in human neurons that protects against the degeneration of motor neurons in the deadly diseases ALS and SMA. Gene therapy in animal models of these diseases was shown to protect against cell death and increase life expectancy. The study is published in the eminent journal Acta Neuropathologica.

Amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA) are deadly diseases characterised by a gradual loss of motor neurons. Since these neurons control all voluntary muscles in the body, this loss leads to muscular atrophy, weakness and paralysis. However, some motor neurons are more sensitive than others, so that those in the spinal cord, for example, are extremely sensitive to degeneration, while the ocular motor neurons in the brain stem, which we use to move our eyes, are highly resistant.

Researchers at Karolinska Institutet and the University of Milan have now identified a gene, Synaptotagmin 13 (SYT13), that is relatively abundant in resistant oculomotor neurons in mice, rats and humans compared with the sensitive motor neurons in the spinal cord. SYT13 codes for (gives rise to) a protein that belongs to a group of membrane proteins.

In experiments with human motor neurons formed from induced pluripotent stem cells (iPS cells) taken from ALS and SMA patients, the researchers were able to show that the introduction of SYT13 protects the cells from degeneration by reducing endoplasmatic reticulum (ER) stress and blocking programmed cell death. The gene had a protective effect regardless of the genetic causes of the diseases.

"This is extremely useful from a therapeutic perspective, since the mechanisms behind neuronal loss are largely unknown in 90 per cent of all ALS patients and can differ from one individual to another," says Eva Hedlund, researcher at the Department of Neuroscience, Karolinska Institutet, and one of the senior authors of the study.

On conducting gene therapy experiments in animal models of ALS and SMA, the team was then able to show that the introduction of SYT13 saves sensitive motor neurons from degeneration in both diseases. The treated mice also lived up to 50 per cent longer in the case of SMA and 14 per cent longer in the case of ALS.

"Our results suggest that SYT13 is a very promising gene therapy candidate for patients with motor neuron disease," says Monica Nizzardo, researcher of the Centro Dino Ferrari, University of Milan, IRCCS Fondazione Ca' Granda, Ospedale Maggiore Policlinico, and first author of the study.

There are currently no effective treatments for ALS and its causes are known only in the 10 per cent of patients that present with familial inherited disease. SMA, on the other hand, is caused by mutations in a gene called survival motor neuron 1 (SMN1). Two new SMA therapies targeted at SMN1 were recently approved with very promising results, but the benefits vary depending on the time of treatment and the degree of disease severity.

"New complementary treatments for SMA and a form of therapy that helps all patients with ALS, regardless of pathogenesis, are needed," says Stefania Corti, researcher of the Centro Dino Ferrari, University of Milan, IRCCS Fondazione Ca' Granda, Ospedale Maggiore Policlinico, and the other senior author of the study.

"We'll continue looking for additional factors that are unique to resistant motor neurons, and thus identify more potential therapeutic targets," says Eva Hedlund.
-end-
The research was financed by the EU Joint Programme Neurodegenerative Disease (JPND), the Thierry Latran Foundation, the Swedish Research Council, the Söderberg Foundation, the Åhlén Foundation, the Birgit Backmark endowment for ALS research at Karolinska Institutet in memory of Hans and Nils Backmark, the Ulla-Carin Lindquist Foundation for ALS Research, the Björklund Fund, the Swedish Society for Medical Research, the Cariplo Foundation, the Italian Ministry of Health,Telethon, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and Karolinska Institutet.

Publication: "Synaptotagmin 13 is neuroprotective across motor neuron diseases". M. Nizzardo, M. Taiana, F. Rizzo, J. Aguila Benitez, J. Nijssen, I. Allodi, V. Melzi, N. Bresolin, G.P. Comi, E. Hedlund och S. Corti. Acta Neuropathologica, online 17 February 2020, doi: 10.1007/s00401-020-02133-x.

Karolinska Institutet

Related Gene Therapy Articles:

Gene therapy/gene editing combo could offer hope for some genetic disorders
A hybrid approach that combines elements of gene therapy with gene editing converted an experimental model of a rare genetic disease into a milder form, significantly enhancing survival, shows a multi-institutional study led by the University of Pennsylvania and Children's National Hospital in Washington, D.C.
Using gene therapy to treat chronic traumatic encephalopathy
A new study shows the feasibility of using gene therapy to treat the progressive neurodegenerative disorder chronic traumatic encephalopathy (CTE).
New technology allows control of gene therapy doses
Scientists at Scripps Research in Jupiter have developed a special molecular switch that could be embedded into gene therapies to allow doctors to control dosing.
Gene therapy: Development of new DNA transporters
Scientists at the Institute of Pharmacy at Martin Luther University Halle-Wittenberg (MLU) have developed new delivery vehicles for future gene therapies.
Non-viral gene therapy to speed up cancer research
A new treatment method promises to speed up gene therapy research and could bring new, patient friendly cancer treatments to market faster.
Gene therapy promotes nerve regeneration
Researchers from the Netherlands Institute for Neuroscience and the Leiden University Medical Center have shown that treatment using gene therapy leads to a faster recovery after nerve damage.
Gene therapy for blood disorders
Delivering gene-regulating material to cells that live deep in our bone marrow and direct the formation of blood cells.
Realizing the potential of gene therapy for neurological disorders
Promising findings from preclinical animal studies show the potential of gene therapy for treating incurable neurological disorders.
Gene therapy vectors carrying the telomerase gene do not increase the risk of cancer
Researchers from the Spanish National Cancer Research Centre (CNIO) have shown in a new study that the gene therapy with telomerase that they have developed, and which has proven to be effective in mice against diseases caused by excessive telomere shortening and ageing, does not cause cancer or increase the risk of developing it, even in a cancer-prone setting.
Study advances gene therapy for glaucoma
In a study published today in the scientific journal Investigative Ophthalmology and Visual Science, Kaufman and Curtis Brandt, a fellow professor of ophthalmology and visual sciences at UW-Madison, showed an improved tactic for delivering new genes into the eye's fluid drain, called the trabecular meshwork.
More Gene Therapy News and Gene Therapy Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at Radiolab.org/donate.